Latest Breaking News On - Neuronopathic gaucher disease - Page 1 : comparemela.com

Company expects completion of IND-enabling studies of GT-02287 in H1 2023Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson’s Disease expected by mid-year. | March 23, 2023

Eteläuomen läiMatthias alderMichaelj fox foundation for parkinson researchSilverstein foundation for parkinsonExchange commission onEuropean union horizonInstitute for researchExchange commissionGain therapeutics incCompany annual report on formUniversity of helsinkiChief executiveStructurally targeted allosteric regulatorReduces microgliosisImproves fine locomotor skillsNeuronopathic gaucher disease